Inflammation in COPD patients before and after roflumilast treatment

摘要: Background.Most of the clinical features COPD are determined by cytokines, chemokines and growth factors. Roflumilast is a phosphodiesterase type 4 inhibitor, producing an anti-inflammatory effect. It administered orally as single daily dose, it was developed treatment to diminish chronic inflammation patients, although its effect on level cytokines involved in polarization CD4+ T cells unknown Aim. Determine if able reduce concentration pro-inflammatory chemokines, impacting CD4 + subpopulations Material methods. Twenty-four patients with diagnose (GOLD guidelines), candidates treatment. Peripheral samples were taken, baseline simple another 8 weeks after Through flow cytometry proportion defined. Serum quantified through Luminex system Results. All subjects had low respiratory function (FEV 1 28 (18-36)%) After showed significant reduction (IL-1b, IL-6 e IL-17) (IL-8, eotaxin, IP-10 y MCP-1). Th17 reduced (pre 5.8±1.5, post 5.4±1.6, p=0.0367) Treg increased 7.7±1.4, 8.8±1.3, p=0.0000) Conclusions. This study shows that capable reducing period short weeks. During this time can be observe decrease increase suggests change microenvironment might lead development certain mechanisms.